Report Detail
Global and Japan RNA Interference (RNAi) Drug Delivery Market Insights, Forecast to 2026
- RnM4199293 |
- 10 September, 2020 |
- Global |
- 149 Pages |
- QYResearch |
- Medical Devices & Consumables
RNA Interference (RNAi) Drug Delivery market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global RNA Interference (RNAi) Drug Delivery market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the RNA Interference (RNAi) Drug Delivery market is segmented into
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Segment by Application, the RNA Interference (RNAi) Drug Delivery market is segmented into
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
Regional and Country-level Analysis
The RNA Interference (RNAi) Drug Delivery market is analysed and market size information is provided by regions (countries).
The key regions covered in the RNA Interference (RNAi) Drug Delivery market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and RNA Interference (RNAi) Drug Delivery Market Share Analysis
RNA Interference (RNAi) Drug Delivery market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in RNA Interference (RNAi) Drug Delivery business, the date to enter into the RNA Interference (RNAi) Drug Delivery market, RNA Interference (RNAi) Drug Delivery product introduction, recent developments, etc.
The major vendors covered:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
1 Study Coverage
- 1.1 RNA Interference (RNAi) Drug Delivery Product Introduction
- 1.2 Market Segments
- 1.3 Key RNA Interference (RNAi) Drug Delivery Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Type
- 1.4.2 Nanoparticle Drug Delivery Technology
- 1.4.3 Pulmonary Drug Delivery Technology
- 1.4.4 Nucleic Acid Drug Delivery Technology
- 1.4.5 Aptamer Drug Delivery Technology
- 1.5 Market by Application
- 1.5.1 Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Application
- 1.5.2 Infectious Diseases
- 1.5.3 Cardiology
- 1.5.4 Oncology
- 1.5.5 Neurology
- 1.5.6 Ophthalmology
- 1.5.7 Metabolic Disorders
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global RNA Interference (RNAi) Drug Delivery Market Size, Estimates and Forecasts
- 2.1.1 Global RNA Interference (RNAi) Drug Delivery Revenue 2015-2026
- 2.1.2 Global RNA Interference (RNAi) Drug Delivery Sales 2015-2026
- 2.2 Global RNA Interference (RNAi) Drug Delivery, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.3 RNA Interference (RNAi) Drug Delivery Historical Market Size by Region (2015-2020)
- 2.3.1 Global RNA Interference (RNAi) Drug Delivery Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.3.2 Global RNA Interference (RNAi) Drug Delivery Retrospective Market Scenario in Revenue by Region: 2015-2020
- 2.4 RNA Interference (RNAi) Drug Delivery Market Estimates and Projections by Region (2021-2026)
- 2.4.1 Global RNA Interference (RNAi) Drug Delivery Sales Forecast by Region (2021-2026)
- 2.4.2 Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Region (2021-2026)
3 Global RNA Interference (RNAi) Drug Delivery Competitor Landscape by Players
- 3.1 Global Top RNA Interference (RNAi) Drug Delivery Sales by Manufacturers
- 3.1.1 Global RNA Interference (RNAi) Drug Delivery Sales by Manufacturers (2015-2020)
- 3.1.2 Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Manufacturers (2015-2020)
- 3.2 Global RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue
- 3.2.1 Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturers (2015-2020)
- 3.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global RNA Interference (RNAi) Drug Delivery Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by RNA Interference (RNAi) Drug Delivery Revenue in 2019
- 3.2.5 Global RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Global RNA Interference (RNAi) Drug Delivery Price by Manufacturers
- 3.4 Global RNA Interference (RNAi) Drug Delivery Manufacturing Base Distribution, Product Types
- 3.4.1 RNA Interference (RNAi) Drug Delivery Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers RNA Interference (RNAi) Drug Delivery Product Type
- 3.4.3 Date of International Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Type (2015-2020)
- 4.1.1 Global RNA Interference (RNAi) Drug Delivery Sales by Type (2015-2020)
- 4.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2015-2020)
- 4.1.3 RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type (2021-2026)
- 4.2.1 Global RNA Interference (RNAi) Drug Delivery Sales Forecast by Type (2021-2026)
- 4.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Type (2021-2026)
- 4.2.3 RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global RNA Interference (RNAi) Drug Delivery Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Application (2015-2020)
- 5.1.1 Global RNA Interference (RNAi) Drug Delivery Sales by Application (2015-2020)
- 5.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Application (2015-2020)
- 5.1.3 RNA Interference (RNAi) Drug Delivery Price by Application (2015-2020)
- 5.2 RNA Interference (RNAi) Drug Delivery Market Size Forecast by Application (2021-2026)
- 5.2.1 Global RNA Interference (RNAi) Drug Delivery Sales Forecast by Application (2021-2026)
- 5.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Application (2021-2026)
- 5.2.3 Global RNA Interference (RNAi) Drug Delivery Price Forecast by Application (2021-2026)
6 Japan by Players, Type and Application
- 6.1 Japan RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2015-2026
- 6.1.1 Japan RNA Interference (RNAi) Drug Delivery Sales YoY Growth 2015-2026
- 6.1.2 Japan RNA Interference (RNAi) Drug Delivery Revenue YoY Growth 2015-2026
- 6.1.3 Japan RNA Interference (RNAi) Drug Delivery Market Share in Global Market 2015-2026
- 6.2 Japan RNA Interference (RNAi) Drug Delivery Market Size by Players (International and Local Players)
- 6.2.1 Japan Top RNA Interference (RNAi) Drug Delivery Players by Sales (2015-2020)
- 6.2.2 Japan Top RNA Interference (RNAi) Drug Delivery Players by Revenue (2015-2020)
- 6.3 Japan RNA Interference (RNAi) Drug Delivery Historic Market Review by Type (2015-2020)
- 6.3.1 Japan RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2015-2020)
- 6.3.2 Japan RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type (2015-2020)
- 6.3.3 Japan RNA Interference (RNAi) Drug Delivery Price by Type (2015-2020)
- 6.4 Japan RNA Interference (RNAi) Drug Delivery Market Estimates and Forecasts by Type (2021-2026)
- 6.4.1 Japan RNA Interference (RNAi) Drug Delivery Sales Forecast by Type (2021-2026)
- 6.4.2 Japan RNA Interference (RNAi) Drug Delivery Revenue Forecast by Type (2021-2026)
- 6.4.3 Japan RNA Interference (RNAi) Drug Delivery Price Forecast by Type (2021-2026)
- 6.5 Japan RNA Interference (RNAi) Drug Delivery Historic Market Review by Application (2015-2020)
- 6.5.1 Japan RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2015-2020)
- 6.5.2 Japan RNA Interference (RNAi) Drug Delivery Revenue Market Share by Application (2015-2020)
- 6.5.3 Japan RNA Interference (RNAi) Drug Delivery Price by Application (2015-2020)
- 6.6 Japan RNA Interference (RNAi) Drug Delivery Market Estimates and Forecasts by Application (2021-2026)
- 6.6.1 Japan RNA Interference (RNAi) Drug Delivery Sales Forecast by Application (2021-2026)
- 6.6.2 Japan RNA Interference (RNAi) Drug Delivery Revenue Forecast by Application (2021-2026)
- 6.6.3 Japan RNA Interference (RNAi) Drug Delivery Price Forecast by Application (2021-2026)
7 North America
- 7.1 North America RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2015-2026
- 7.2 North America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
- 7.2.1 North America RNA Interference (RNAi) Drug Delivery Sales by Country (2015-2020)
- 7.2.2 North America RNA Interference (RNAi) Drug Delivery Revenue by Country (2015-2020)
- 7.2.3 U.S.
- 7.2.4 Canada
8 Europe
- 8.1 Europe RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2015-2026
- 8.2 Europe RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
- 8.2.1 Europe RNA Interference (RNAi) Drug Delivery Sales by Country
- 8.2.2 Europe RNA Interference (RNAi) Drug Delivery Revenue by Country
- 8.2.3 Germany
- 8.2.4 France
- 8.2.5 U.K.
- 8.2.6 Italy
- 8.2.7 Russia
9 Asia Pacific
- 9.1 Asia Pacific RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2015-2026
- 9.2 Asia Pacific RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
- 9.2.1 Asia Pacific RNA Interference (RNAi) Drug Delivery Sales by Region (2015-2020)
- 9.2.2 Asia Pacific RNA Interference (RNAi) Drug Delivery Revenue by Region
- 9.2.3 China
- 9.2.4 Japan
- 9.2.5 South Korea
- 9.2.6 India
- 9.2.7 Australia
- 9.2.8 Taiwan
- 9.2.9 Indonesia
- 9.2.10 Thailand
- 9.2.11 Malaysia
- 9.2.12 Philippines
- 9.2.13 Vietnam
10 Latin America
- 10.1 Latin America RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2015-2026
- 10.2 Latin America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
- 10.2.1 Latin America RNA Interference (RNAi) Drug Delivery Sales by Country
- 10.2.2 Latin America RNA Interference (RNAi) Drug Delivery Revenue by Country
- 10.2.3 Mexico
- 10.2.4 Brazil
- 10.2.5 Argentina
11 Middle East and Africa
- 11.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2015-2026
- 11.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
- 11.2.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales by Country
- 11.2.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Revenue by Country
- 11.2.3 Turkey
- 11.2.4 Saudi Arabia
- 11.2.5 U.A.E
12 Company Profiles
- 12.1 Metabolic disorders
- 12.1.1 Metabolic disorders Corporation Information
- 12.1.2 Metabolic disorders Description and Business Overview
- 12.1.3 Metabolic disorders Sales, Revenue and Gross Margin (2015-2020)
- 12.1.4 Metabolic disorders RNA Interference (RNAi) Drug Delivery Products Offered
- 12.1.5 Metabolic disorders Recent Development
- 12.2 Alnylam Pharmaceuticals Inc
- 12.2.1 Alnylam Pharmaceuticals Inc Corporation Information
- 12.2.2 Alnylam Pharmaceuticals Inc Description and Business Overview
- 12.2.3 Alnylam Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.2.4 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.2.5 Alnylam Pharmaceuticals Inc Recent Development
- 12.3 Merck & Co. Inc
- 12.3.1 Merck & Co. Inc Corporation Information
- 12.3.2 Merck & Co. Inc Description and Business Overview
- 12.3.3 Merck & Co. Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.3.4 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.3.5 Merck & Co. Inc Recent Development
- 12.4 Access Pharmaceuticals Inc
- 12.4.1 Access Pharmaceuticals Inc Corporation Information
- 12.4.2 Access Pharmaceuticals Inc Description and Business Overview
- 12.4.3 Access Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.4.4 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.4.5 Access Pharmaceuticals Inc Recent Development
- 12.5 Dicerna Pharmaceuticals Inc
- 12.5.1 Dicerna Pharmaceuticals Inc Corporation Information
- 12.5.2 Dicerna Pharmaceuticals Inc Description and Business Overview
- 12.5.3 Dicerna Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.5.4 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.5.5 Dicerna Pharmaceuticals Inc Recent Development
- 12.6 Calondo Pharmaceuticals Inc
- 12.6.1 Calondo Pharmaceuticals Inc Corporation Information
- 12.6.2 Calondo Pharmaceuticals Inc Description and Business Overview
- 12.6.3 Calondo Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.6.4 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.6.5 Calondo Pharmaceuticals Inc Recent Development
- 12.7 Marina Biotech Inc
- 12.7.1 Marina Biotech Inc Corporation Information
- 12.7.2 Marina Biotech Inc Description and Business Overview
- 12.7.3 Marina Biotech Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.7.4 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.7.5 Marina Biotech Inc Recent Development
- 12.8 RXi Pharmaceuticals Corp
- 12.8.1 RXi Pharmaceuticals Corp Corporation Information
- 12.8.2 RXi Pharmaceuticals Corp Description and Business Overview
- 12.8.3 RXi Pharmaceuticals Corp Sales, Revenue and Gross Margin (2015-2020)
- 12.8.4 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Products Offered
- 12.8.5 RXi Pharmaceuticals Corp Recent Development
- 12.9 Quark Pharmaceuticals Inc
- 12.9.1 Quark Pharmaceuticals Inc Corporation Information
- 12.9.2 Quark Pharmaceuticals Inc Description and Business Overview
- 12.9.3 Quark Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.9.4 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.9.5 Quark Pharmaceuticals Inc Recent Development
- 12.10 Silence Therapeutics plc
- 12.10.1 Silence Therapeutics plc Corporation Information
- 12.10.2 Silence Therapeutics plc Description and Business Overview
- 12.10.3 Silence Therapeutics plc Sales, Revenue and Gross Margin (2015-2020)
- 12.10.4 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Products Offered
- 12.10.5 Silence Therapeutics plc Recent Development
- 12.11 Metabolic disorders
- 12.11.1 Metabolic disorders Corporation Information
- 12.11.2 Metabolic disorders Description and Business Overview
- 12.11.3 Metabolic disorders Sales, Revenue and Gross Margin (2015-2020)
- 12.11.4 Metabolic disorders RNA Interference (RNAi) Drug Delivery Products Offered
- 12.11.5 Metabolic disorders Recent Development
- 12.12 PhaseRx Inc
- 12.12.1 PhaseRx Inc Corporation Information
- 12.12.2 PhaseRx Inc Description and Business Overview
- 12.12.3 PhaseRx Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.12.4 PhaseRx Inc Products Offered
- 12.12.5 PhaseRx Inc Recent Development
- 12.13 Sirnaomics Inc
- 12.13.1 Sirnaomics Inc Corporation Information
- 12.13.2 Sirnaomics Inc Description and Business Overview
- 12.13.3 Sirnaomics Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.13.4 Sirnaomics Inc Products Offered
- 12.13.5 Sirnaomics Inc Recent Development
- 12.14 Traversa Therapeutics Inc
- 12.14.1 Traversa Therapeutics Inc Corporation Information
- 12.14.2 Traversa Therapeutics Inc Description and Business Overview
- 12.14.3 Traversa Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.14.4 Traversa Therapeutics Inc Products Offered
- 12.14.5 Traversa Therapeutics Inc Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter’s Five Forces Analysis
- 13.5 Primary Interviews with Key RNA Interference (RNAi) Drug Delivery Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 RNA Interference (RNAi) Drug Delivery Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on RNA Interference (RNAi) Drug Delivery. Industry analysis & Market Report on RNA Interference (RNAi) Drug Delivery is a syndicated market report, published as Global and Japan RNA Interference (RNAi) Drug Delivery Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of RNA Interference (RNAi) Drug Delivery market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
